Afluria Vaccine Approved for Patients 6 Months and Older

The U.S. Food and Drug Administration (FDA) has approved AFLURIA QUADRIVALENT, an Influenza Vaccine, for use in people 6 months of age and older. 

This FDA approval also applies to the trivalent formulation of AFLURIA®. 

AFLURIA QUADRIVALENT was first approved by the FDA during August 2016, for use in adults 18+ years and above. 

AFLURIA QUADRIVALENT is available in the U.S. for the 2018-2019 influenza season. 

Gregg Sylvester MD, Vice President of Medical Affairs at Seqirus, said in a press release, “Having another option to fight this disease can translate to saved lives and fewer flu-related hospitalizations this season and going forward.” 

AFLURIA helps protect against two influenza A strain viruses, and two B strain viruses. 

Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. 

To reduce the risk of more serious influenza-related outcomes, such as hospitalization and death, the CDC encourages annual vaccination for all individuals aged 6 months and older. 

Since it takes about 2 weeks after vaccination for antibodies to develop in the body that protects against influenza virus infection, it is best that people get vaccinated to help protect them before influenza begins spreading in their community. 

The vaccine is available in single-dose, preservative-free pre-filled syringes and multi-dose vials to provide choice and convenience to patients and caregivers who administer it. 

Please see the accompanying Important Safety Information and the US full Prescribing Information for AFLURIA QUADRIVALENT.

• Afluria is a trivalent influenza vaccine developed with egg-based technologies and is indicated for persons aged five or older.
• Afluria is available in both prefilled syringes and multi-dose vials to provide choice and convenience to patients and caregivers who administer it.
• It is the only trivalent flu vaccine with a needle-free delivery option (PharmaJet® Stratis® 0.5mL Needle-Free Jet Injector) for persons 18 through 64 years of age.

The complete Seqirus portfolio of seasonal influenza vaccines provides a range of options for children aged six months of age to people aged 65 years and older, including egg-based and cell-based technologies and adjuvant.